Business Standard

Monday, December 30, 2024 | 10:32 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

New launches to prop sales recovery as GSK Pharma gets over Zinetac pain

Near-term gains may be limited given restrictions which will impact anti-infectives portfolio

GSK, PHARMA, GLAXO
Premium

The company recently sold its Vemgal plant in Karnataka to Hetero Labs for Rs 180 crore

Ram Prasad Sahu Mumbai
The GlaxoSmithKline Pharmaceuticals (GSK Pharma) stock has underperformed the overall pharma market over the last one year on account of lower sales in the anti-infectives category.

The company recently sold its Vemgal plant in Karnataka to Hetero Labs for Rs 180 crore. The plant had remained unutilised after the company took a decision to discontinue production of heartburn drug Zinetac. The company took a Rs 640 crore write-off last year and was looking at a buyer for the plant.

Given that the book value of the assets stood at Rs 375 crore, the company will take a Rs 195 crore

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in